A Phase 2 interventional study of Ebselen and Placebo in Hearing Loss and Cochlear Trauma, sponsored by Sound Pharmaceuticals, Incorporated. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.
Among the 321 studies in Hearing Loss with a site in United States, this one is the 149th largest by planned enrollment of the 272 interventional ones that give a count, is one of 25 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 21 of the 93 other live ones, and was the 260th registered.
796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
University of Arizona · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 25–55 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–89
City of Hope Medical Center · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 31 · Phase 3 5 · Phase 4 5
First in 1997; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 44 across 561 interventional studies indexed under Hearing Loss.
Median enrollment 48 across the 272 interventional studies, 79 across the 48 observational. Of the 202 that completed or were terminated, 98 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 321 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 9 studies filed under Hearing Loss — fewer than ten, so there is no comparison to draw.
34 of the studies in Hearing Loss with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT07913776Sonova AGPerformance of a Remote Microphone Compared to Hearing Aids Alone | 2026-11-30 |
| NCT05260307Boston University Charles River CampusImproving Spatial Perception and Speech Understanding in Multitalker Mixtures | 2026-11-30 |
| NCT06340633Sound Pharmaceuticals, IncorporatedSPI-1005 in Adults Receiving Cochlear Implant | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 321 studies in Hearing Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear.
The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005?
The clinical trial will also measure the effects of SPI-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. The purpose for this and future clinical trials is to learn whether SPI-1005 can prevent or treat these side effects after receiving a cochlear implant.
Participants will take drug SPI-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. There are 5 required in-clinic visits over 6 months for audiology and other tests.
The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Air conduction thresholds (decibel hearing loss, dB HL) at baseline in the ear scheduled to receive the cochlear implant:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration of ebselen (SPI-1005) 400 mg BID for 180 days
Drug: Ebselen
Oral administration of matching placebo BID for 180 days
Drug: Placebo
Glutathione peroxidase mimetic
Also known as: SPI-1005
Matching placebo containing excipients
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Number and severity of adverse events in patients treated with placebo versus SPI-1005. Outcome Measure 1 includes all adverse events, including those which are not reported in the Adverse Event module, i.e., adverse events which did not result in death, were not Serious Adverse Events, and which were below the frequency threshold (5%) in any arm as required for reporting.
Time frame: 12 months
Effect of SPI-1005 on Residual Low Frequency Hearing
Residual hearing at low frequencies (≤1000 Hz) using pure tone audiometry
Time frame: 12 months
Effect of SPI-1005 on Word Recognition
Word recognition using words in quiet
Time frame: 12 months
Effect of SPI-1005 on Speech Discrimination
Speech discrimination using words in noise
Time frame: 12 months
Effect of SPI-1005 on Tinnitus
Tinnitus severity using the Tinnitus Functional Index (TFI). TFI Total Score: 0-100, in which a higher score means a worse outcome.
Time frame: 12 months
Effect of SPI-1005 on Vertigo
Vertigo severity using the Vertigo Symptoms Scale (VSS). VSS Total Scale: 0-60, in which a higher score means a worse outcome.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebselen
Sound Pharmaceuticals, Incorporated